title: 18-Methoxycoronaridine, a potential anti-obesity agent, does not produce a conditioned taste aversion in rats.
abstract: 18-Methoxycoronaridine (18-MC), a selective antagonist of alpha3beta4 nicotinic receptors, has been shown to reduce the self-administration of several drugs of abuse. Recently, this agent has also been shown to attenuate sucrose reward, decrease sucrose intake and prevent the development of sucrose-induced obesity in rats. The present experiments were designed to determine whether the latter effect was due to an 18-MC-induced conditioned taste aversion to sucrose. Both 18-MC (20mg/ kg, i.p.) and control agent, lithium chloride (100mg/kg, i.p.), reduced sucrose intake 24h after association with sucrose; however, only lithium chloride reduced sucrose intake 72h later. Consistent with previous data, 18-MC appears to have proactive effect for 24h and it does not induce a conditioned taste aversion.
authors.affiliation: Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, NY, USA. tarasco@mail.amc.edu
authors.forename: Olga D
authors.initials: OD
authors.lastname: Taraschenko
authors.forename: Isabelle M
authors.initials: IM
authors.lastname: Maisonneuve
authors.forename: Stanley D
authors.initials: SD
authors.lastname: Glick
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D001362:Avoidance Learning / Q000187:drug effects*; D003216:Conditioning, Operant / Q000187:drug effects*; D004435:Eating / Q000187:drug effects; D005260:Female; D007050:Ibogaine / Q000031:analogs & derivatives* / Q000494:pharmacology; D018021:Lithium Chloride; D051381:Rats; D017207:Rats, Sprague-Dawley; D013395:Sucrose; D013649:Taste / Q000187:drug effects*
chemical_list: D019440:Anti-Obesity Agents; D007050:Ibogaine; D013395:Sucrose; D018021:Lithium Chloride; C103345:18-methoxycoronaridine
references.citation: Behav Brain Res. 1994 Dec 15;65(2):123-37
references.pmid: 7718144
references.citation: Neuroreport. 2000 Jun 26;11(9):2013-5
references.pmid: 10884062
references.citation: Am J Physiol Regul Integr Comp Physiol. 2000 Jul;279(1):R132-40
references.pmid: 10896874
references.citation: Neurosci Biobehav Rev. 2005;29(7):1107-18
references.pmid: 16084590
references.citation: Brain Res. 1996 May 6;719(1-2):29-35
references.pmid: 8782860
references.citation: Neuropharmacology. 2002 Mar;42(4):530-9
references.pmid: 11955523
references.citation: Psychopharmacology (Berl). 2008 Dec;201(3):339-50
references.pmid: 18751969
references.citation: J Clin Invest. 2005 Dec;115(12):3564-72
references.pmid: 16322794
references.citation: Behav Pharmacol. 1995 Jun;6(4):375-385
references.pmid: 11224346
references.citation: Eur J Pharmacol. 2008 Feb 2;580(1-2):143-52
references.pmid: 18031736
references.citation: Eur J Pharmacol. 2002 Mar 1;438(1-2):99-105
references.pmid: 11906717
references.citation: Pharmacol Biochem Behav. 1988 May;30(1):235-42
references.pmid: 3174748
references.citation: Eur Neuropsychopharmacol. 2008 Jul;18(7):508-18
references.pmid: 18343642
references.citation: Addict Biol. 2006 Mar;11(1):45-54
references.pmid: 16759336
references.citation: Neuropharmacology. 2008 Feb;54(2):445-53
references.pmid: 18078963
references.citation: J Exp Psychol Anim Behav Process. 1976 Jan;2(1):17-27
references.pmid: 1249524
references.citation: Neuroreport. 1998 May 11;9(7):1283-5
references.pmid: 9631413
references.citation: Pharmacol Biochem Behav. 2003 Jun;75(3):607-18
references.pmid: 12895678
references.citation: Science. 1955 Jul 22;122(3160):157-8
references.pmid: 14396377
references.citation: J Neurophysiol. 2008 Feb;99(2):644-55
references.pmid: 17913985
references.citation: J Comp Physiol Psychol. 1969 Apr;67(4):421-9
references.pmid: 5787393
references.citation: Behav Neurosci. 2009 Aug;123(4):764-71
references.pmid: 19634934
references.citation: J Exp Psychol Anim Behav Process. 1977 Jan;3(1):66-76
references.pmid: 845544